Valuation: Assembly Biosciences, Inc.

Market Cap 573M 502M 462M 429M 814M 54.62B 825M 5.53B 2.15B 26.81B 2.15B 2.1B 92.96B P/E 2026 *
-26.7x
P/E 2027 * -10.1x
Enterprise Value 573M 502M 462M 429M 814M 54.62B 825M 5.53B 2.15B 26.81B 2.15B 2.1B 92.96B EV / Sales 2026 *
12.6x
EV / Sales 2027 * 17.8x
Free-Float
71.58%
Yield 2026 *
-
Yield 2027 * -
1 day+4.16%
1 week+7.18%
Current month+5.15%
1 month+26.18%
3 months-1.11%
6 months-5.51%
Current year-15.04%
1 week 26.06
Extreme 26.06
29
1 month 21.8
Extreme 21.795
29
Current year 21.8
Extreme 21.795
34.68
1 year 16.9
Extreme 16.9
39.7
3 years 7.69
Extreme 7.692
39.7
5 years 7.69
Extreme 7.692
47.28
10 years 7.69
Extreme 7.692
808.32
Manager TitleAgeSince
Chief Executive Officer 50 01/01/2023
Director of Finance/CFO - 05/06/2025
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 70 04/06/2026
Director/Board Member 61 14/12/2017
Director/Board Member 68 06/08/2019
Date Insider Type Main position Quantity % Market Cap.
06-17Sell

Chief Financial Officer

-29 0.0002%
06-04Free

Chairman

8,000 0.0514%
06-04Free

Director

8,000 0.0514%
Change 5-day change 1-year change 3-year change Capi.($)
+4.16%+7.18%+59.29%+125.04% 573M
+0.16%+6.38%+4.05%+10.59% 50.25B
+0.40%-1.37%+401.69%+625.15% 40.39B
-0.52%+6.57%+25.41%-5.37% 34.38B
+3.97%+6.71%+26.06%+63.36% 34.4B
-4.19%-1.84%+3.76%+32.17% 26.32B
-2.40%+1.60% - - 16.64B
+1.34%+5.68%+75.77%+141.51% 16.14B
+1.19%+1.40%+15.33%+22.52% 13.71B
+1.69%+3.09%+93.44%+99.19% 13.75B
Average +0.58%+4.64%+78.31%+123.80% 24.66B
Weighted average by Cap. +0.22%+4.06%+91.55%+142.02%

Financials

2026 *2027 *
Net sales 45.47M 39.82M 36.68M 34.05M 64.65M 4.34B 65.53M 439M 171M 2.13B 171M 167M 7.38B 32.25M 28.24M 26.01M 24.15M 45.86M 3.08B 46.48M 311M 121M 1.51B 121M 118M 5.24B
Net income -20.46M -17.92M -16.51M -15.32M -29.1M -1.95B -29.49M -198M -76.9M -958M -76.85M -75.16M -3.32B -56.38M -49.38M -45.48M -42.21M -80.16M -5.38B -81.25M -544M -212M -2.64B -212M -207M -9.15B
Net Debt - -
Logo Assembly Biosciences, Inc.
Assembly Biosciences, Inc. is a biotechnology company, which is engaged in the development of small-molecule therapeutics designed to change the path of serious viral diseases and improve the lives of patients worldwide. Its pipeline includes multiple clinical-stage investigational therapies, including two helicase-primase inhibitors (HPI) targeting recurrent genital herpes; an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, and a potent next-generation capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. Its pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses, which is undergoing studies to enable a regulatory filing, and it also has additional research programs against multiple antiviral targets. It is advancing two investigational long-acting HPI candidates, ABI-5366 (5366) and (2) ABI-1179 (1179).
Employees
73
Date Price Change Volume
06/07/26 $28.90 +4.16% 179,400
02/07/26 $27.74 +3.93% 199,257
01/07/26 $26.69 -2.87% 204,110
30/06/26 $27.48 +1.93% 249,382
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
28.90USD
Average target price
50.00USD
Spread / Average Target
+73.04%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ASMB Stock